Ghassan Abou-Alfa, MD (Liver Cancer)

Memorial Sloan-Kettering Cancer Center, New York, USA

Dr. Ghassan Abou-Alfa specializes in Hepatocellular Cancer as an Associate Member of Memorial Sloan-Kettering and Associate Professor of Medicine in Joan & Sanford I. Weill Medical College of Cornell University since 2012. He received his M.D. degree in American University of Beirut and served on the faculty of the department of Medicine in Yale University School of Medicine before he joined Memorial Sloan-Kettering Cancer Center where he is appointed as an associate attending add to his associate professorship at Joan & Sanford I. Weill Medical Scholl at Cornell University.

Dr. Abou-Alfa’s research is dedicated to finding novel therapies and improving the effectiveness current therapies for hepatocellular carcinoma, while continuing to understand the basic mechanisms of the disease and its therapies. Dr Abou-Alfa has many publications in the field of hepatocellular carcinoma. He led on many occasions, international teams of investigators, and published the first report on the effective role of the novel agent sorafenib in the treatment of primary liver cancer and the role of adding doxorubicin to sorafenib. One of Dr. Abou-Alfa key interests is developing therapeutic strategies that help overcome resistance to sorafenib. Dr. Abou-Alfa serves as the vice Chair of the National Cancer Institute (NCI) Task Force for Hepatobiliary Cancers. Dr Abou-Alfa chairs the hepatocellular carcinoma subgroup of the Alliance cooperative group, and is a cadre member of both the gastrointestinal cancers and pharmacogenomics and population pharmacology committees. Dr Abou-Alfa who has lectured worldwide on the subject on gastrointestinal malignancies, is also a strong advocate for raising awareness and support for improving the outcome of patients with this disease, and enhancing oncologic education worldwide.